Although the TERIKIDS study failed to meet its primary endpoint, pediatric patients with multiple sclerosis (MS) had similar benefits from therapy to adult patients, researchers reported at the EAN Virtual Congress. As Dr Tanuja Chitnis from the Massachusetts General Hospital for Children, Boston, USA, explained, high crossover from the placebo group to active therapy biased the results against treatment efficacy.